Atrial Fibrillation Management and Electrophysiological Mechanisms

Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia worldwide, placing a heavy burden on healthcare systems and patients due to its association with stroke, heart failure and mortality. Management strategies centre on two complementary approaches: rate control to stabilise ventricular response and rhythm control to restore and maintain sinus rhythm. Rhythm control encompasses antiarrhythmic drugs, catheter- or surgical-based ablation techniques and emerging device-based neuromodulation. The cornerstone of ablation remains pulmonary vein isolation, though persistent and long-standing forms of AF often demand substrate modification targeting areas of electrical dispersion and structural remodelling. Underlying these clinical interventions is a complex interplay of electrophysiological mechanisms: focal ectopic activity originating from the pulmonary veins, re-entrant circuits facilitated by atrial tissue heterogeneity, and progressive electrical and structural remodelling driven by genetic predisposition, inflammation and oxidative stress. Advances in computational modelling, genetics and artificial intelligence are now enabling personalised risk stratification, improved procedural planning and novel mechanism-based therapies aimed at the molecular drivers of electropathology.

Research from Nature Portfolio

Recent genetic analyses spanning diverse ancestries have uncovered numerous novel susceptibility loci for AF, elucidating immune and transcriptional regulators as causal mediators. Integrative studies using human induced pluripotent stem cell-derived cardiomyocytes have identified key transcription factors that govern atrial gene networks, while polygenic risk scoring now offers predictive value for cardioembolic stroke in undiagnosed individuals. Complementing these findings, a comprehensive primer on AF pathophysiology has synthesised current knowledge of electropathology, delineating how molecular defects in ion-handling proteins and signalling pathways give rise to conduction disorders. This work outlines a framework for personalised diagnostics and mechanism-guided therapies, emphasising holistic strategies that combine lifestyle modification, pharmaceutical intervention, substrate-based ablation and neuromodulation to optimise rhythm control and long-term outcomes.

Atrial Fibrillation Management and Electrophysiological Mechanisms publication trend

The graph below shows the total number of articles in atrial fibrillation management and electrophysiological mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

Atrial fibrillation: Supraventricular tachyarrhythmia characterised by rapid, disorganised electrical activation of the atria.

Catheter ablation: Minimally invasive procedure in which targeted energy (radiofrequency or cryothermal) is delivered to cardiac tissue to eliminate arrhythmogenic foci or pathways.

Pulmonary vein isolation: Ablation strategy that electrically disconnects the pulmonary veins from the left atrium to prevent ectopic impulses from triggering AF.

Genome-wide association study: Large-scale analysis of common genetic variants across the genome to identify loci associated with disease susceptibility.

Polygenic risk score: Aggregate measure of genetic risk derived from the sum of risk alleles weighted by their effect sizes, used for disease prediction.

Electropathology: Molecular and cellular alterations—including ion-channel dysfunction and structural remodelling—that disrupt normal electrical conduction in cardiac tissue.

References

1. Cross-ancestry genome-wide analysis of atrial fibrillation unveils disease biology and enables cardioembolic risk prediction. Nature Genetics (2023).
2. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: Executive summary. EP Europace (2017).
3. Long‐term Outcomes of Catheter Ablation of Atrial Fibrillation: A Systematic Review and Meta‐analysis. Journal of the American Heart Association (2013).
4. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovascular Diabetology (2017).
5. Atrial fibrillation. Nature Reviews Disease Primers (2022).